NEO Neogenomics Inc - 8-K

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 23, 2025, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") accepted the resignation of Dr. Alison L. Hannah as a director of the Company effective December 31, 2025.

On December 23, 2025, the Board of the Company appointed Jack Kenny as a member of the Board effective January 1, 2026 to fill the vacancy created by Dr. Hannah's resignation.

Mr. Kenny will serve as a member of the Board until the 2026 annual meeting of stockholders of the Company or until his resignation or removal and otherwise until his successor is elected. Mr. Kenny will receive compensation for his service as an independent director consistent with the Company's director compensation program previously disclosed in the Company's definitive proxy statement for its 2025 annual meeting of stockholders. There are no transactions in which Mr. Kenny has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Item 7.01

Regulation FD Disclosure

On December 29, 2025, the Company issued a press release regarding the foregoing, which is attached to the Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(a)

Not applicable

(b)

Not applicable

(c)

Not applicable

(d)

Exhibits.

99.1

Press Release of NeoGenomics, Inc. dated December 29, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).